Clinical course in Parkinson's disease with elevated homocysteine

Padraig E. O'Suilleabhain, Robert Oberle, Cristina Bartis, Richard B. Dewey, Teodoro Bottiglieri, Ramon Diaz-Arrastia

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Elevated homocysteine (Hcy), prevalent in Parkinson's disease (PD), is potentially a modifiable risk factor for neurologic deterioration. We measured cognitive, affective and motor changes over 2 years in a cohort of people with early PD. Subjects whose Hcy had been elevated (>14 μmol/L, n=31) at baseline were compared with the rest (n=66). Overall progression in 2 years did not significantly differ (p=0.20). Four subjects with elevated and one with normal Hcy had died (p=0.03). We conclude that hyperhomocysteinemia does not predict significantly worse progression over 2 years in early PD. The data raised the possibility of higher mortality, but the number of deaths was small.

Original languageEnglish (US)
Pages (from-to)103-107
Number of pages5
JournalParkinsonism and Related Disorders
Issue number2
StatePublished - Mar 2006


  • Cognition
  • Homocysteine
  • Parkinson's disease
  • Vitamins

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology


Dive into the research topics of 'Clinical course in Parkinson's disease with elevated homocysteine'. Together they form a unique fingerprint.

Cite this